Opsona Therapeutics Ltd. Initiates a Phase II Study With OPN-305, a First-in Class Monoclonal Antibody That Blocks Toll-Like Receptor 2, in Renal Transplant Patients at High Risk of Delayed Graft Function
5/7/2013 11:19:59 AM
More...
|
Opsona Therapeutics Ltd. Raises $43 Million to Develop Lead Product
4/29/2013 6:56:26 AM
More...
|
Opsona Therapeutics Ltd. Announces the Issuance of New Patent From the European Patent Office (EPO) Covering the Development and Use of an Antibody Directed Against Toll-like Receptor TLR-2
4/17/2012 10:24:23 AM
More...
|
Opsona Therapeutics Ltd. Adds 3.3 Million Euro to Series B
5/20/2009 8:13:04 AM
More...
|
Galapagos NV (GLPG.BR) And Opsona Therapeutics Ltd. Initiate Drug Discovery Collaboration
4/21/2009 12:11:23 PM
More...
|
Opsona Therapeutics Ltd., CSL Limited (CMXHF.PK) Form Vaccine Adjuvant R&D Collaboration Targeting Infectious Diseases And Oncology
2/23/2009 11:59:18 AM
More...
|
Opsona Therapeutics Ltd. Closes E18 Million Funding
2/18/2009 7:06:23 AM
More...
|
Opsona Therapeutics Ltd. Announces A Collaboration With Wyeth (WYE) On Toll-Like Receptors
2/13/2006 1:06:38 PM
More...
|
Irish Pharma Start-Up Opsona Therapeutics Ltd. Raises $8.3 Million (EUR6.25 Million) Series A
10/19/2005 5:12:51 PM
More...
|